– ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment – – Data will be featured in ...
LONDON, Dec 10 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine ...
LONDON, Dec 10 (Reuters) - Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, in what it said ...
Speaking with FRANCE 24's Carys Garland, David Camroux, Senior Researcher & Adjunct Professor at Sciences Po CERI, explains that there is no political will to resolve the border dispute due to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback